業績

2013年度研究業績
  1. 佐藤 克也, 西田 教行 【感染症症候群(第2版)-症候群から感染性単一疾患までを含めて-[上]】 プリオン病 遺伝性プリオン病 ゲルストマン・ストロイスラー・シャインカー病. 日本臨床. 2013;別冊(感染症症候群(上)):792-7.
  2. 佐藤 克也, 新 竜一郎, 西田 教行. 検査からみる神経疾患 髄液14-3-3蛋白とタウ蛋白増加の鑑別診断. Clinical Neuroscience. 2013;31(7):850-1.
  3. 佐藤 克也, 新 竜一郎, 西田 教行. 【プリオン病-up to date】 プリオン病の診断と治療 髄液検査のポイントと鑑別診断. Clinical Neuroscience. 2013;31(9):1080-2.
  4. 佐藤 克也, 新 竜一郎, 西田 教行. プリオン病の髄液診断の可能性. 最新医学. 2013;68(9):1950-7.
  5. Satoh K. [CSF analysis of patients with prion disease by biomarkers and real-time qucking-induced conversion (RT-QUIC) method]. Rinsho Shinkeigaku. 2013;53(11):1252-4.
  6. Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS One. 2013;8(1):e54915.
  7. Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Med. 2013;11:182.
  8. Nakagaki T, Satoh K, Ishibashi D, Fuse T, Sano K, Kamatari YO, et al. FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. Autophagy. 2013;9(9):1386-94.
  9. Ishizaka S, Horie N, Satoh K, Fukuda Y, Nishida N, Nagata I. Intra-arterial cell transplantation provides timing-dependent cell distribution and functional recovery after stroke. Stroke. 2013;44(3):720-6.
  10. Higuma M, Sanjo N, Satoh K, Shiga Y, Sakai K, Nozaki I, et al. Relationships between clinicopathological features and cerebrospinal fluid biomarkers in Japanese patients with genetic prion diseases. PLoS One. 2013;8(3):e60003.
  11. Hara S, Henmi T, Kawakami A, Fujikawa K, Mukae H, Ishimatsu Y, et al. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. 2013;33(4):1059-64.